| |
BEXTRA CLASS ACTION
Bextra is a "COX-2" selective non-steroidal anti-inflammatory drug (NSAID). Bextra was used to reduce pain, inflammation, and stiffness caused by osteoarthritis and adult rheumatoid arthritis. Bextra was also used to treat painful menstruation.
In 2005 however, Bextra was voluntarily taken off the market in both Canada and the U.S. due to safety concerns of an increased risk of cardiovascular events (including heart attack and stroke) in patients taking Bextra.
Bextra was first approved for sale in Canada in December, 2002. At about the same time, reports were surfacing linking Bextra to serious, potentially life-threatening skin reactions such as Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome, as by 2004, there were also reports of adverse cardiovascular events such as heart attacks and strokes, infections and other complications associated with using Bextra. It is alleged that Pfizer Canada, the drug's Canadian manufacturer, knew about these life-threatening risks much sooner, but failed to inform Canadian physicians and consumers.
Pfizer Canada is the Canadian operation of New York based Pfizer Inc, the world's largest pharmaceutical company. Pfizer Inc. reported revenues of 48.4 billion in 2007.
If you or someone you know has been affected by the use of Bextra and you would like to find out more information click here to contact us. |
|